Cellect Biotechnology (NASDAQ:APOP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, March 20th. The brokerage currently has a $8.00 price objective on the stock. Zacks Investment Research’s target price suggests …
13
Apr
Leave a Reply
You must be logged in to post a comment.